HRS-9821 vs TQC3721

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: PDE3/PDE4 · full Chronic Obstructive Pulmonary Disease pipeline

HRS-9821

Developed by GlaxoSmithKline and partners

Phase 2 in Chronic Obstructive Pulmonary Diseasesmall molecule
Weak signal

NCT05622864 · Phase 1 · completed

The study is described as randomized and blinded, but the available record does not clearly show a placebo or comparator arm alongside the two active-dose groups, so how controlled the comparison actually is cannot be fully confirmed. Its primary measure is also safety monitoring rather than the lung-function endpoints, and no results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Assess the incidence and severity of adverse events after single atomization inhalation of HRS-9821 in healthy subjects and multiple atomization inhalation of HRS-9821 in COPD patients.". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

TQC3721

Developed by AstraZeneca under a licence from Sino Biopharmaceutical

Phase 3 in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT06527144 · Phase 2 · completed

The trial randomized 240 participants to two TQC3721 doses or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinically relevant lung-function measure FEV1. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Next expected readout: February 2027 · NCT07464587 (registry estimate)

Reported efficacy

Change of the maximum value of Forced Expiratory Volume in the first second (FEV1) (From baseline to four weeks after treatment): Primary endpoint, change in peak FEV1 at week 4 vs placebo: 3 mg +100 mL (95% CI 41 to 159; P = .0011); 6 mg +147 mL (95% CI 93 to 201; P < .0001) (PACER-II, CHEST 2026). (met)

Result source: NCT06527144

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHRS-9821TQC3721
Moderate or severe exacerbations, annualised rate—Not reported—Trial running · NCT07147946
Trough FEV1, change—Not reported—Trial running · NCT07147946
SGRQ total, change—Not reported—Trial running · NCT07147946
TDI focal score—Not reported—Trial running · NCT07147946

Moderate or severe exacerbations, annualised rate

HRS-9821
—Not reported
TQC3721
—Trial running · NCT07147946

Trough FEV1, change

HRS-9821
—Not reported
TQC3721
—Trial running · NCT07147946

SGRQ total, change

HRS-9821
—Not reported
TQC3721
—Trial running · NCT07147946

TDI focal score

HRS-9821
—Not reported
TQC3721
—Trial running · NCT07147946
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-9821: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

TQC3721
Primary endpoint, change in peak FEV1 at week 4 vs placebo: 3 mg +100 mL (95% CI 41 to 159; P = .0011); 6 mg +147 mL (95% CI 93 to 201; P < .0001) (PACER-II, CHEST 2026). NCT06527144 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-9821's landscape · TQC3721's landscape